Pediatric Optic Pathway Gliomas: A Report From Northern Greece

被引:1
作者
Panagopoulou, Paraskevi [1 ]
Athanasiadis, Dimitrios [2 ]
Anastasiou, Athanassia [3 ]
Zafeiriou, Dimitrios [4 ]
Papakonstantinou, Evgenia [2 ]
机构
[1] Aristotle Univ Thessaloniki, Dept Pediat 4, Thessaloniki, Greece
[2] Ippokration Hosp, Dept Pediat Oncol, Thessaloniki, Greece
[3] Ippokration Hosp, Dept Pediat Radiol, Thessaloniki, Greece
[4] Aristotle Univ Thessaloniki, Ippokration Hosp, Dept Pediat 1, Thessaloniki, Greece
关键词
optic pathway glioma; low-grade glioma; brain tumors; chemotherapy; neurofibromatosis type 1; LOW-GRADE GLIOMA; SPONTANEOUS REGRESSION; BRAIN-TUMOR; CHILDREN; OUTCOMES; CLASSIFICATION; ASTROCYTOMAS; RADIOTHERAPY; EXPERIENCE; RADIATION;
D O I
10.1097/MPH.0000000000002753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Optic pathway gliomas (OPGs) are the most common pediatric optic nerve tumors. Their behavior ranges between rapid growth, stability, or spontaneous regression. tau hey are characterized by low mortality albeit with significant morbidity. We present the characteristics, management, and outcome of 23 OPG patients (16 females, median age: 4.8 y) managed in a Pediatric Oncology Department in Northern Greece over a 25-year period. Overall, 57% had a background of neurofibromatosis type 1. Diagnosis was based on imaging (10 patients) or biopsy (13 patients). Presenting symptoms were mostly visual impairment/squint (52%). Proptosis/exophthalmos, raised intracranial pressure, and headache were also noted. In 2 occasions, it was detected with surveillance magnetic resonance imaging in the context of neurofibromatosis type 1. Eight patients had unilateral and 2 bilateral optic nerve tumors (Modified Dodge Classification, stage 1a/1b), 3 had chiasmatic (stage 2a/b), and 10 had multiple tumors (stage 3/4). Predominant histology was pilocytic astrocytoma (77%). Management included: observation (4), chemotherapy only (9), surgery only (3), or various combinations (7). Chemotherapy regimens included vincristine and carboplatin, vinblastine, or bevacizumab with irinotecan. Most patients demonstrated a slow disease course with complete response/partial response to chemotherapy and/or surgery, whereas 39% presented >= 1 recurrences. After a median follow-up of 8.5 years (range to 19 y), 20 patients (87%) are still alive with stable disease, in partial/complete remission, or on treatment.
引用
收藏
页码:445 / 451
页数:7
相关论文
共 49 条
  • [1] Pediatric Optic Pathway/Hypothalamic Glioma
    Aihara, Yasuo
    Chiba, Kentaro
    Eguchi, Seiichiro
    Amano, Kosaku
    Kawamata, Takakazu
    [J]. NEUROLOGIA MEDICO-CHIRURGICA, 2018, 58 (01) : 1 - 9
  • [2] [Anonymous], 2022, DAY101 vs. standard of care chemotherapy in pediatric patients with low-grade glioma requiring first-line systemic therapy (LOGGIC/FIREFLY-2)
  • [3] Optic Pathway Gliomas Secondary to Neurofibromatosis Type 1
    Beres, Shannon Jeanine
    Avery, Robert A.
    [J]. SEMINARS IN PEDIATRIC NEUROLOGY, 2017, 24 (02) : 92 - 99
  • [4] Optic Pathway Gliomas in Neurofibromatosis Type 1
    Campen, Cynthia J.
    Gutmann, David H.
    [J]. JOURNAL OF CHILD NEUROLOGY, 2018, 33 (01) : 73 - 81
  • [5] Cardellicchio S, 2014, NEUROPEDIATRICS, V45, P42, DOI 10.1055/s-0033-1360482
  • [6] Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations
    Cassina, Matteo
    Frizziero, Luisa
    Opocher, Enrico
    Parrozzani, Raffaele
    Sorrentino, Ugo
    Viscardi, Elisabetta
    Miglionico, Giacomo
    Midena, Edoardo
    Clementi, Maurizio
    Trevisson, Eva
    [J]. CANCERS, 2019, 11 (11)
  • [7] Fractionated stereotactic radiotherapy of optic pathway gliomas: Tolerance and long-term outcome
    Combs, SE
    Schulz-Ertner, D
    Moschos, D
    Thilmann, C
    Huber, PE
    Debus, J
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (03): : 814 - 819
  • [8] Optic pathway gliomas in children with and without neurofibromatosis 1
    Czyzyk, E
    Józwiak, S
    Roszkowski, M
    Schwartz, RA
    [J]. JOURNAL OF CHILD NEUROLOGY, 2003, 18 (07) : 471 - 478
  • [9] Inhibition of ERK/MAPK signaling as potential therapy to prevent optic pathway glioma in infants with neurofibromatosis type 1
    D'Angelo, Fulvio
    Lasorella, Anna
    [J]. DEVELOPMENTAL CELL, 2021, 56 (20) : 2785 - 2786
  • [10] Optic pathway glioma in children: 10years of experience in a single institution
    Doganis, Dimitrios
    Pourtsidis, Apostolos
    Tsakiris, Kleonikos
    Baka, Margarita
    Kouri, Agathi
    Bouhoutsou, Despina
    Varvoutsi, Maria
    Servitzoglou, Marina
    Dana, Helen
    Kosmidis, Helen
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2016, 33 (02) : 102 - 108